FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655229> ?p ?o ?g. }

• W4385655229 endingPage "e2794388" @default.
• W4385655229 startingPage "e2794388" @default.
• W4385655229 abstract "Topic: 17. Hodgkin lymphoma - Clinical Background: Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard treatment for patients with relapsed/refractory Hodgkin lymphoma (R/R HL). The choice of a salvage treatment protocol should be based on arguments of efficacy (overall response rate), its effectiveness in mobilizing and collecting stem cells, and also on arguments of tolerance (low toxicity). Aims:- Primary objective: assess the toxicity of different salvage chemotherapy (CT) regimens in adult patients with R/R HL. -Secondary objective: compare salvage chemotherapy regimens in order to determine the optimal treatment. Methods: A retrospective study, including 41 patients with R/R HL treated in the Clinical Hematology department between January 2014 and December 2020.The treatment regimens used in our study were DHAP (Dexamethasone-Cytosine arabinoside-Cisplatin), ICE (Ifosfamide-Carboplatin-Etoposide), IGEV (Ifosfamide-Gemcitabine-Vinorelbine) and BVB (BrentuximabVedotin- Bendamustine) followed by ASCT in good responders. Results: The median age was 34 years (18-67 years) with male predominance (sex ratio 1.05). Salvage therapy was indicated for refractory HL in 34 patients (83%) and for relapsed HL in 7 cases (17%). One hundred courses of DHAP were administered in 26 cases: 52 courses were received in 2nd line chemotherapy (CT) in 14 cases and 48 courses in 3rd line CT by 12 patients. The two main toxicities of this regimen were grade 3-4 hematological toxicity (neutropenia, thrombocytopenia) in 30 courses (30%) and grade 3-4 renal toxicity in 3 courses (3%) resulting in the discontinuation of the DHAP. No toxic deaths were reported with DHAP. Ninety-two cycles of IGEV were administered in 25 cases: 89 courses were received in the 2nd line in 24 cases, and 3 courses in the 3rd line in one case. Grade 3-4 thrombocytopenia and neutropenia, infectious toxicity and Grade 1 renal toxicity were seen in 23 (25%), 5 and 1 cycle respectively. Twelve courses of ICE were administered to four patients: 4 as 3rd line in one case and 8 as 4th line in 3 cases. Grade 3-4 hematological toxicity was seen in 2 cycles of ICE (16%). Seventy BVB cycles were received in 14 cases: 14 as 2nd line, 44 as 3rd line and 12 as 4th line. No toxicity was seen. The treatment was discontinued in one case because of death due to disease progression. There was no statistically significant difference in terms of hematological toxicity between DHAP, IGEV and ICE (p=0.286). This may be due to the reduced number of patients. Summary/Conclusion: Compared with DHAP, IGEV and ICE, the BVB regimen has less toxicity in R/R HL. Given the small number of courses more data are needed to confirm these results. Keywords: Hodgkin’s lymphoma, Chemotherapy toxicity, Hematotoxicity" @default.
• W4385655229 created "2023-08-09" @default.
• W4385655229 creator A5007660781 @default.
• W4385655229 creator A5029723151 @default.
• W4385655229 creator A5030673546 @default.
• W4385655229 creator A5034448170 @default.
• W4385655229 creator A5035304141 @default.
• W4385655229 creator A5046279721 @default.
• W4385655229 creator A5051209457 @default.
• W4385655229 creator A5059669388 @default.
• W4385655229 creator A5062573042 @default.
• W4385655229 date "2023-08-01" @default.
• W4385655229 modified "2023-10-14" @default.
• W4385655229 title "PB2263: TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA." @default.
• W4385655229 doi "https://doi.org/10.1097/01.hs9.0000975784.27943.88" @default.
• W4385655229 hasPublicationYear "2023" @default.
• W4385655229 type Work @default.
• W4385655229 citedByCount "0" @default.
• W4385655229 crossrefType "journal-article" @default.
• W4385655229 hasAuthorship W4385655229A5007660781 @default.
• W4385655229 hasAuthorship W4385655229A5029723151 @default.
• W4385655229 hasAuthorship W4385655229A5030673546 @default.
• W4385655229 hasAuthorship W4385655229A5034448170 @default.
• W4385655229 hasAuthorship W4385655229A5035304141 @default.
• W4385655229 hasAuthorship W4385655229A5046279721 @default.
• W4385655229 hasAuthorship W4385655229A5051209457 @default.
• W4385655229 hasAuthorship W4385655229A5059669388 @default.
• W4385655229 hasAuthorship W4385655229A5062573042 @default.
• W4385655229 hasBestOaLocation W43856552291 @default.
• W4385655229 hasConcept C126322002 @default.
• W4385655229 hasConcept C141071460 @default.
• W4385655229 hasConcept C143998085 @default.
• W4385655229 hasConcept C2776694085 @default.
• W4385655229 hasConcept C2777063308 @default.
• W4385655229 hasConcept C2777506904 @default.
• W4385655229 hasConcept C2778119113 @default.
• W4385655229 hasConcept C2778239845 @default.
• W4385655229 hasConcept C2779050716 @default.
• W4385655229 hasConcept C2780258809 @default.
• W4385655229 hasConcept C2780775027 @default.
• W4385655229 hasConcept C2781413609 @default.
• W4385655229 hasConcept C2781451048 @default.
• W4385655229 hasConcept C71924100 @default.
• W4385655229 hasConcept C90924648 @default.
• W4385655229 hasConceptScore W4385655229C126322002 @default.
• W4385655229 hasConceptScore W4385655229C141071460 @default.
• W4385655229 hasConceptScore W4385655229C143998085 @default.
• W4385655229 hasConceptScore W4385655229C2776694085 @default.
• W4385655229 hasConceptScore W4385655229C2777063308 @default.
• W4385655229 hasConceptScore W4385655229C2777506904 @default.
• W4385655229 hasConceptScore W4385655229C2778119113 @default.
• W4385655229 hasConceptScore W4385655229C2778239845 @default.
• W4385655229 hasConceptScore W4385655229C2779050716 @default.
• W4385655229 hasConceptScore W4385655229C2780258809 @default.
• W4385655229 hasConceptScore W4385655229C2780775027 @default.
• W4385655229 hasConceptScore W4385655229C2781413609 @default.
• W4385655229 hasConceptScore W4385655229C2781451048 @default.
• W4385655229 hasConceptScore W4385655229C71924100 @default.
• W4385655229 hasConceptScore W4385655229C90924648 @default.
• W4385655229 hasIssue "S3" @default.
• W4385655229 hasLocation W43856552291 @default.
• W4385655229 hasLocation W43856552292 @default.
• W4385655229 hasOpenAccess W4385655229 @default.
• W4385655229 hasPrimaryLocation W43856552291 @default.
• W4385655229 hasRelatedWork W149876398 @default.
• W4385655229 hasRelatedWork W2018507611 @default.
• W4385655229 hasRelatedWork W2064115395 @default.
• W4385655229 hasRelatedWork W2131794718 @default.
• W4385655229 hasRelatedWork W2229794545 @default.
• W4385655229 hasRelatedWork W2327780098 @default.
• W4385655229 hasRelatedWork W2397387063 @default.
• W4385655229 hasRelatedWork W2789166760 @default.
• W4385655229 hasRelatedWork W6933653 @default.
• W4385655229 hasRelatedWork W2133000900 @default.
• W4385655229 hasVolume "7" @default.
• W4385655229 isParatext "false" @default.
• W4385655229 isRetracted "false" @default.
• W4385655229 workType "article" @default.